181073-82-5

Basic information

• Product Name: 4-CYANO-2,6-DIFLUOROBENZOIC ACID
• Synonyms: 4-Cyano-2,6-difluorobenzoicacid
• CAS NO: 181073-82-5
• Molecular Formula: C₈H₃F₂NO₂
• Molecular Weight: 183.11
• Mol File: 181073-82-5.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 303.895 °C at 760 mmHg
• Flash Point: 137.591 °C
• Appearance: /
• Density: 1.518 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.54
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 1.68±0.10(Predicted)
• CAS DataBase Reference: 4-CYANO-2,6-DIFLUOROBENZOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 4-CYANO-2,6-DIFLUOROBENZOIC ACID(181073-82-5)
• EPA Substance Registry System: 4-CYANO-2,6-DIFLUOROBENZOIC ACID(181073-82-5)

Safety Data

• Hazardous Substances Data: 181073-82-5(Hazardous Substances Data)

Usage

General Description

4-Cyano-2,6-difluorobenzoic acid is a chemical compound with the molecular formula C9H4F2NCOOH. It is a derivative of benzoic acid with a cyano and two fluoro substituents. 4-CYANO-2,6-DIFLUOROBENZOIC ACID is commonly used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. It has several applications in the field of organic chemistry, including as a building block in the production of various fine chemicals. Its properties and structure make it useful in the development of new compounds and materials for a wide range of industrial and research applications.

InChI:InChI=1/C8H3F2NO2/c9-5-1-4(3-11)2-6(10)7(5)8(12)13/h1-2H,(H,12,13)

Upstream product

• 124-38-9 carbon dioxide 
• 64248-63-1 3,5-difluorobenzonitrile 
• 467442-15-5 3,5-difluoro-4-formylbenzonitrile 

Downstream Products

• 181073-83-6 [6-(4-cyano-2,6-difluoro-benzoylamino)-1-oxo-1,2,3,4-tetrahydro-naphthalen-2-yl]-acetic acid ethyl ester 
• 267242-16-0 [6-(4-carbamimidoyl-2,6-difluoro-benzoylamino)-1-oxo-1,2,3,4-tetrahydro-naphthalen-2-yl]-acetic acid ethyl ester 
• 267242-12-6 {6-[4-(tert-Butoxycarbonylamino-imino-methyl)-2,6-difluoro-benzoylamino]-1-oxo-1,2,3,4-tetrahydro-naphthalen-2-yl}-acetic acid ethyl ester 
• 1270977-92-8 4-[(4-{3-cyano-2-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propyl}piperazin-1-yl)carbonyl]-3,5-difluorobenzonitrile 
• 1270977-93-9 4-[(4-{3-cyano-2-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propyl}piperazin-1-yl)carbonyl]-3,5-difluorobenzonitrile phosphate 
• 1329166-87-1 4-aminomethyl-2,6-difluorobenzoic acid 
• 622847-30-7 4-(tert-butoxycarbonylaminomethyl)-2,6-difluorobenzoic acid 
• 1355664-52-6 4-cyano-2,6-difluorobenzoyl chloride 
• 1418293-07-8 (R)-N-(1-(dimethylamino)propan-2-yl)-2,6-difluoro-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide 
• 1418293-50-1 2,6-difluoro-4-(N'-hydroxycarbamimidoyl)benzoic acid 
• 1418293-51-2 2,6-difluoro-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzoic acid 

Relevant articles and documents

THIAZOLE DERIVATIVES FOR THE TREATMENT OF ANIMAL TRYPANOSOMIASIS

The present invention relates to a novel class of compounds of general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, X and Y are as defined herein, to their use in human and veterinary medicine, and in the treatment of animal trypanosomiasis in particular, to compositions containing them, to processes for their preparation and to intermediates used in such processes.

NOVEL TRIFLUOROMETHYL-OXADIAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE

The invention relates to novel trifluoromethyl-oxadiazole derivatives of formula (I), and pharmaceutically acceptable salts thereof, (I) in which all of the variables are as defined in the specification, pharmaceutical compositions thereof, pharmaceutical combinations thereof, and their use as medicaments, particularly for the treatment of neurodegeneration, muscle atrophy or metabolic syndrome via inhibition of HDAC4.

MACROCYCLES AS FACTOR XIA INHIBITORS

The present invention provides compounds of Formula (I): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein all the variables are as defined herein. These compounds are selective Factor XIa inhibitors or dual inhibitors of fXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.